Vaccine Adjuvant That Bypasses the Cold Chain

Tech ID: 30617 / UC Case 2018-290-0

Background

Most vaccines are required to be stored at low temperatures to ensure that they remain safe and effective when administered to patients.  The temperature-controlled supply chain for vaccines is known as the cold chain. The cold chain ensures that vaccines are refrigerated from production until they are administered to patients.  Unfortunately, the cold chain may not be accessible to some parts of the world without reliable sources of electricity.  For this reason, it may be difficult to vaccinate people living in these remote areas.  Vaccines that bypass cold chain logistics are desirable to help increase vaccinations and to decrease costs.

Brief Description

Dr. David Lo and his colleagues at UCR have developed a new vaccine adjuvant that is composed of engineered cross-linked polymeric flagellin.  This new adjuvant stabilizes vaccines so that it may bypass the cold chain and may potentially increase vaccination rates in remote areas without a reliable source of electricity. 
Another aspect of this flagellin adjuvant is that it may induce a T helper independent immune response.  This immune response may be desirable in patients with T cell immunodeficiency disorders.

Gries1

Fig. 1 is a schematic that shows disulfide bonds between neighboring flagellin filaments. The covalently stabilized flagellar filament provides additional immune efficacy through the stabilization of its polymeric filament structure and this contributes to the long-term storage of a vaccine absent the cold chain

Gries2

Fig. 2 shows the long term temperature stability of the adjuvant in solution. Less than 50% of the engineered adjuvant was degraded after being heated to 42°C for 7 days.

 

Applications

This new adjuvant will be more cost effective and the following patients may benefit from it:

  • Patients having different T cell immunodeficiency disorders such as AIDS or DiGeorge syndrome
  • Patients undergoing chemotherapy
  • Perinatal or elderly individuals with weak immune systems
  • Patients in remote areas

Patent Status

Patent Pending

Related Materials

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information

Keywords

adjuvant, T cell independent, flagellin, immunodeficiency disorders, cold chain

Categorized As